
To assess the zzso dose zzso zzso toxicity zzso zzso and zzso activity of zzso administered in combination with zzso 

Patients were treated with zzso zzso zzso on day 1 and zzso IV on days zzso of a zzso zzso The starting dose zzso 1) was zzso 60 zzso and zzso 25 zzso zzso analysis was performed at various zzso before and after zzso 

Twenty patients received a total of 49 courses of treatment on zzso At dose level 2 zzso 60 zzso zzso 45 zzso two patients experienced zzso zzso zzso grade 4 zzso An additional three patients were enrolled at dose level 1 without initial zzso Enrollment then resumed at dose level zzso with a decreased dose of zzso zzso zzso with zzso 45 zzso The two patients enrolled on this level had two zzso zzso zzso Enrollment was planned to resume at dose level 1; however, the sixth patient enrolled to this cohort developed grade 5 heart failure zzso fraction zzso zzso zzso zzso after the second zzso Thus, zzso and zzso were reduced to 45 and 25 zzso respectively zzso zzso prior to zzso enrollment at dose level 1, the zzso The main drug-related toxicity was zzso zzso zzso included zzso fatigue, grade 3 zzso and grade 4 zzso There was one zzso death due to heart zzso While no objective responses were observed, zzso evidence of clinical activity was observed in patients with zzso melanoma and prostate zzso 

zzso patients with advanced zzso can tolerate the combination of zzso and zzso at doses that achieve zzso clinical benefit with the main zzso zzso being zzso and zzso The zzso was determined to be zzso 60 zzso on day 1 and zzso 25 zzso on days zzso of a zzso zzso 

